Evolution of Clinical Trials for Irritable Bowel Syndrome: Issues in End Points and Study Design

@article{Trentacosti2010EvolutionOC,
  title={Evolution of Clinical Trials for Irritable Bowel Syndrome: Issues in End Points and Study Design},
  author={Ann Marie Trentacosti and Ruyi He and Laurie B. Burke and Donna J Griebel and Dianne L Kennedy},
  journal={The American Journal of Gastroenterology},
  year={2010},
  volume={105},
  pages={731-735}
}
Irritable bowel syndrome (IBS) involves a broad range of physiological and psychological alterations that may affect brain–gut dysregulation, gut function, visceral perception, and mucosal integrity and function. Despite advances in our understanding of basic neuroenteric mechanisms and the role of effectors and transmitters in the brain–gut axis, a reliable biologic marker of IBS has yet to be identified (1, 2, 3, 4, 5, 6, 7, 8). IBS diagnosis and status depend entirely on an assessment of IBS… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

A randomized controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation

  • J Tack, S Muller-Lissner, P Bytzer
  • Gut
  • 2005

Similar Papers

Loading similar papers…